US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the Phase III MOVE-NOW study for its oral antiviral COVID-19 medicine, Lagevrio (molnupiravir), in adults with COVID-19 who are at high risk for disease progression. This trial marks a significant step in the ongoing development and evaluation of effective treatments for COVID-19.
New Formulation of Lagevrio Under Investigation
The trial will investigate a new formulation of Lagevrio, which includes two smaller 400-mg tablets per dose, requiring a total of four daily tablets, as opposed to the current regimen of four 200-mg capsules per dose, which equates to eight daily capsules. This change in formulation aims to enhance patient compliance and ease of administration.
Molnupiravir: A Prodrug Active Against Coronaviruses
Molnupiravir, the active ingredient in Lagevrio, is a prodrug of ribonucleoside analog β-D-N4-hydroxycytidine (NHC) and was co-developed by Ridgeback Biotherapeutics. It exhibits activity against coronaviruses and other RNA viruses by interfering with the genetic coding of the virus, introducing errors, and preventing virus replication.
Global Approvals and Emergency Use Authorization
Lagevrio has received approval or authorization for use in several countries, including Japan and Australia. In the United States, the drug is available for use under emergency use authorization for the treatment of certain adults diagnosed with COVID-19. The MOVE-NOW study aims to further establish the efficacy and safety profile of Lagevrio, potentially expanding its use in the global fight against the pandemic.-Fineline Info & Tech
